Novocure announced that the International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, has published the results of an EF-14 post-hoc analysis demonstrating that higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients. The simulation-based, post-hoc analysis included 340 patients from the EF-14 phase 3 pivotal trial, which compared Tumor Treating Fields plus temozolomide versus temozolomide alone for the treatment of newly diagnosed GBM. All EF-14 patients who were on treatment for at least two months and who had MRIs of acceptable quality were included. The median overall survival and progression free survival were significantly longer when the average dose density in the tumor bed was greater than0.77 mW/cm3: overall survival and progression free survival.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.